291
Participants
Start Date
July 31, 2010
Primary Completion Date
August 31, 2011
Study Completion Date
April 30, 2016
PROMUS(TM) Element (TM) Stent System
The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
Evolution Stent System
The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
Middlemore Hospital, Otahuhu
Academisch Ziekenhuis Middelheim, Antwerp
Rigshospitalet Thoraxkirurgisk Klinik RT, Copenhagen
UZ Gasthuisberg, Leuven
Ziekenhuis Oost Limburg, Genk
Centre Hospitalier Universitaire Sart Tilman Liège, Liège
Fremantle Hospital, Fremantle
Skejby Sygehus, Aarhus
Dunedin Hospital, Dunedin
Hospital Clinico San Carlos, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Virgen de la Arrixaca, El Palmar
Hôpital Rangueil, Toulouse
Clinique Pasteur, Toulouse
Hôpital Cochin, Paris
Falu lasarett, Falun
Polyclinique Les Fleurs, Ollioules
The Prince Charles Hospital, Chermside
Monash Medical Centre, Clayton
St. Vincent's Hospital (Melbourne), Fitzroy
North Shore Hospital, Takapuna
Szpital Uniwersytecki im. dr. Antoniego Jurasza w Bydgoszczy, Bydgoszcz
Hospital Clinic i Provincial de Barcelona, Barcelona
Uppsala Akademiska Hospital, Uppsala
Royal Victoria Hospital, Belfast
Papworth Hospital, Cambridge
Golden Jubilee National Hospital, Clydebank
Liverpool Heart and Chest Hospital, Liverpool
John Radcliffe Hospital, Oxford
Lead Sponsor
Boston Scientific Corporation
INDUSTRY